Indian Markets Continue Winning Streak, Sensex Closes at ₹72,426

16 Feb 2024 , 04:19 PM

Domestic benchmark indices rose on Friday, marking the 4th consecutive session of gains, supported by sustained domestic buying. The positive trend aligns with the rise in Asian markets following fresh U.S. data signaling a cooling economy.
At the time of closing, Sensex reached ₹72,426 which is a 0.52% hike than the previous close. Whereas Nifty was traded at ₹22,040 which is a 0.59% hike than previous close.

The market has experienced range-bound movements recently, characterized by alternating bouts of selling and buying. Over the last 2 days, Foreign Institutional Investors (FIIs) sold equity worth ₹6993 Crores in the cash market, while Domestic Institutional Investors (DIIs) bought equity worth ₹5173 Crores.

Ajay Singh, Chairman, and Managing Director of SpiceJet, along with Busy Bee Airways Private Limited, jointly submitted a bid for GoFirst. The bid, submitted by Ajay Singh in his personal capacity, aims at acquiring GoFirst.

Lupin Ltd has received approval from the US Food and Drug Administration (USFDA) to market its generic ‘Minzoya’ tablets, which are used to prevent pregnancy. The approval covers strengths of 0.1 mg/0.02 mg and 36.5 mg for Levonorgestrel and Ethinyl Estradiol tablets, and Ferrous Bisglycinate tablets.

Zydus Lifesciences has obtained USFDA approval for its generic drug designed to prevent chest pain in heart patients. The approval is for Isosorbide Mononitrate Extended-Release Tablets USP, with strengths of 30 mg, 60 mg, and 120 mg.

For feedback and suggestions, write to us at [e-mail]